Therapy Areas: Oncology
BreakBio set to enter clinic
25 August 2026 - Personalised cancer immunotherapy company BreakBio Corp announced on Monday that it is entering the clinic next quarter.BreakBio says it is designed for higher efficacy than Moderna&#...
Astellas doses first patient in Phase 3 study of ASP2138
25 August 2026 - Japanese pharmaceutical company Astellas Pharma Inc (TSE:4503) announced on Monday that the first patient has been dosed in a Phase 3 study evaluating ASP2138 in combination with chem...
Gilead expands Trodelvy role in first-line metastatic triple-negative breast cancer in Europe
24 August 2026 - Biopharmaceutical company Gilead Sciences Inc (Nasdaq:GILD) announced on Monday that the European Commission has approved Trodelvy (sacituzumab govitecan-hziy) with Keytruda (pembroli...
GSK's Jemperli wins FDA priority review for advanced rectal cancer
24 August 2026 - Biopharmaceutical company GSK plc (LON:GSK) (NYSE:GSK) announced on Monday that the US Food and Drug Administration (FDA) has accepted for priority review its supplemental Biologics L...
Anbogen Therapeutics enters collaborative research agreement with University of Tokyo for ABT-301 evaluation across multiple tumour types
24 August 2026 - Anbogen Therapeutics Inc (TPEx:7784), a Taiwan-based, clinical-stage precision oncology company, announced on Sunday that it has entered into a Collaborative Research Agreement (CRA) ...
Leads Biolabs NDA for Opamtistomig accepted by China's CDE
21 August 2026 - China-based biotechnology company Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) said on Friday that the Centre for Drug Evaluation of the National Medical Products Administration has ac...